Statin

Statin
Klasa leka
Lovastatin
Lovastatin, ovo jedinjenje izolovano iz Aspergillus terreus je bio prvi stani na tržištu
Identifikatori klase
UpotrebaHiperholesterolemija
ATC kodC10AA
Biološki ciljHMG-CoA reduktaza
Klinički podaci
Drugs.comKlase lekova
Spoljašnje veze
MeSHD019161
Na Vikipodacima

Statini (inhibitori HMG-CoA reduktaze) su klasa lekova koja se koristi za snižavanje nivoa holesterola inhibicijom enzima HMG-CoA reduktaza, koji ima centralnu ulogu u produkciji holesterola u jetri. Povišeni nivoi holesterola su povezani sa kardiovaskularnim bolestima,[1], te se statini koriste za sprečavanje tih bolesti. Istraživanja su pokazala da su statini efektivniji u tretiranu kardiovaskularnih bolesti (sekundarna prevencija).[2][3] Statini imaju retke ali ozbiljne nuspojave, posebno oštećenja mišića, i neki lekari smatraju da se previše koriste.

Statin sa najvećom prodajom je atorvastatin, koji je na tržištu pod imenom Lipitor (Pfizer) i Torvast. Atorvastatin je 2003. postao lek sa najvećom prodajom u istoriji.[4] Pfizer je izvestio da je prodaja 2008. bila američkih dolara 12,4 milijarde.[5] Brojni statini su u prodaji (2010): atorvastatin (Lipitor i Torvast), fluvastatin (Leskol), lovastatin (Mevakor, Altokor, Altoprev), pitavastatin (Livalo, Pitava), pravastatin (Pravahol, Selektin, Lipostat), rosuvastatin (Krestor) i simvastatin (Zokor, Lipeks).[6] Nekoliko kombinacija preparata statatina i nekog drugog agensa, kao što je ezetimib/simvastatin, su takođe dostupni.

Reference

  1. ^ Lewington, S.; Whitlock, G; Clarke, R.; et al. (2007). „Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths”. Lancet. 370 (9602): 1829—39. PMID 18061058. doi:10.1016/S0140-6736(07)61778-4. 
  2. ^ National Institute for Health and Clinical Excellence (2008). „Lipid modification - Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease - Quick reference guide” (PDF). Архивирано из оригинала (PDF) 08. 04. 2011. г. Приступљено 25. 8. 2010. 
  3. ^ Taylor, F; Ward, K; Moore, TH; et al. (2011). Taylor, Fiona, ур. „Statins for the primary prevention of cardiovascular disease”. Cochrane Database Syst Rev (1): CD004816. PMID 21249663. doi:10.1002/14651858.CD004816.pub4. 
  4. ^ Simons, John. "The $10 billion pill" Архивирано на веб-сајту Wayback Machine (20. октобар 2012), Fortune magazine, January 20, 2003.
  5. ^ „"Doing Things Differently"” (PDF). стр. 15. Архивирано из оригинала (PDF) 12. 05. 2013. г. Приступљено 21. 10. 2012. , Pfizer 2008 Annual Review, April 23, (2009).
  6. ^ Sweetman, Sean C., ур. (2009). „Cardiovascular drugs”. Martindale: the complete drug reference (36th изд.). London: Pharmaceutical Press. стр. 1155—434. ISBN 978-0-85369-840-1. 

Literatura

  • Sweetman, Sean C., ур. (2009). „Cardiovascular drugs”. Martindale: the complete drug reference (36th изд.). London: Pharmaceutical Press. стр. 1155—434. ISBN 978-0-85369-840-1. 

Spoljašnje veze

  • Statin page at Bandolier, an evidence-based medicine journal

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.